Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

20261 citationsJournal Article

Authors

Hanny Al-Samkari · Massachusetts General Hospital

Cesar Gregorio Muñoz · Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

Çağlayan Geredeli · Istinye University

I. Korantzis · St. Luke's Hospital

Beatriz González Astorga · Instituto de Investigación Biosanitaria de Granada

Cagatay Arslan · Izmir University

Johnny Francisco Cordeiro Camargo

Abstract

In this phase 3, placebo-controlled trial, romiplostim was efficacious in treating CIT. (Funded by Amgen and the Biomedical Advanced Research and Development Authority; RECITE ClinicalTrials.gov number, NCT03362177.).

Topics & Keywords

Platelet Disorders and Treatments Heparin-Induced Thrombocytopenia and Thrombosis Neutropenia and Cancer Infections

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 11, pp. 1061-1073

DOI: 10.1056/nejmoa2511882

Field-Weighted Citation Impact: 48.40

Command Palette

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

Authors

Abstract

Topics & Keywords

Publication Details